Biotech

All Articles

Merck quits phase 3 TIGIT trial in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has gone through an additional obstacle. Months after shuttering a peri...

After a challenging year, Exscientia folds up right into Recursion

.After a year specified by pipe cuts, the departure of its chief executive officer as well as cutbac...

Cullinan, after $25M package, return bispecific to Harbour

.Cullinan Therapeutics was actually thrilled enough with Harbour BioMed's bispecific invulnerable re...

A nearer check out Fierce Biotech's Strong 15

.In this week's episode of "The Best Line," our experts're diving into Tough Biotech's annual Strong...

Lilly deals with period 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration celebrating the approval of Alzhei...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our summary of notable management hirings, shootings and ...

Lykos will definitely ask FDA to reconsider its choice observing being rejected of MDMA treatment for post-traumatic stress disorder

.Adhering to an inadequate revealing for Lykos Therapies' MDMA candidate for post-traumatic stress d...

AN 2 halves headcount, ceases stage 3 trial after information dissatisfy

.AN2 Therapeutics is actually reconsidering its own service in response to lackluster midphase data,...

Merck pays $700M for bispecific, snooping autoimmune opening and odds to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 thousand beforehand to test Amgen in a blood cancer cell...

Gilead pays out J&ampJ $320M to leave licensing bargain for seladelpar

.With Gilead Sciences on the verge of an FDA choice for its own liver illness medication seladelpar,...